The importance of the age factor in cancer vaccination at older age

Cancer Immunology, Immunotherapy

Volumn 58, Issue 12, 2009, Pages 1969-1977

  Gravekamp, Claudia ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer vaccines; Mage b DNA vaccine; Metastatic breast cancer; Old age; T cell unresponsiveness

Indexed keywords

CANCER VACCINE;

AGING; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW; T LYMPHOCYTE;

AGING; CANCER VACCINES; HUMANS; NEOPLASMS; T-LYMPHOCYTES;

EID: 79958101860     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0683-x     Document Type: Conference Paper

References (81)

1. Gravekamp C, Bontenbal M, Ronteltap C et al (1990) In vitro and in vivo activation of CD4+ lymphocytes by autologous tumor cells. Int J Cancer 46:152-154
2. Schreiber H (1998) Tumor immunology. In: Paul W (ed) Fundamental immunology, 4th edn. Lippencott-Raven, Philadelphia, pp 1237-1270
3. Gravekamp C (2001) Tailoring cancer vaccines to the elderly: the importance of suitable mouse models. MAD 122:1087-1105
4. Koyama S, Maruyama T, Adachi S et al (1998) Expression of costimulatory molecules, B7-1 and B7-2 on human gastric carcinoma. J Can Res Clin Oncol 124:383-388 (Pubitemid 28366018)
5. Maurer CA, Friess H, Kretschmann B et al (1998) Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer 79:76-81 (Pubitemid 28157731)
6. Loo DT, Chalupny NJ, Bajorath J et al (1997) Analysis of 4-IBBL and laminin binding to murine 4-IBB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-IBB. J Biol Chem 272:6448-6456 (Pubitemid 27118124)
7. Melero I, Shuford WW, Newby SA et al (1997) Monoclonal antibodies against the 4-IBB T cell activation molecule eradicate established tumors. Nat Med 3:682-685 (Pubitemid 27264981)
8. Garrido F, Ruiz-Cabello F, Cabrera T et al (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89-95 (Pubitemid 27107103)
9. Akbasak A, Oldfield EH, Saris SC (1991) Expression and modulation of major histocompatibility antigens on murine brain tumors in vitro. J Neurosurg 75:922-929
10. Pedrinaci S, Algarra I, Garcia LA et al (1999) Selective upregulation of MHC class I expression in metastatic colonies derived from tumor clones of a murine fibrosarcoma. Int J Clin Lab Res 29:166-173
11. Weber JS, Rosenberg SA (1990) Effects of murine tumor class I major histocompatibility complex expression on anti-tumor activity of tumor-infiltrating lymphocytes. J Natl Cancer Inst 82:755-761 (Pubitemid 20159275)
12. Blieden TM, McAdam AJ, Foresman MD (1991) Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class- I inducible tumors. Int J Cancer Suppl 6:82-89
13. Corver WE, Koopman LA, van der Aa J et al (2000) Four-color multiparameter DNA Xow cytometry to study phenotypic intratumor heterogeneity in cervical cancer. Cytometry 39:96-107 (Pubitemid 30090461)
14. Sypniewska RK, Hoflack L, Tarango M, Gauntt S, Leal BZ, Reddick RL, Gravekamp C (2005) Prevention of metastases with Mage-b vaccine in a mouse breast tumor model: potential for breast cancer therapy. Breast Cancer Res Treat 91:19-28 (Pubitemid 40684935)
15. Zou W (2006) Regulatory T cell, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307
16. Curiel TJ (2007) Tregs and rethinking cancer immunotherapy. J Clin Investig 117:1167-1174
17. Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253-257 (Pubitemid 37323210)
18. Shimizu J, Yamzaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD4+CD25+ T cells: a common basis between tumor immunityand autoimmunity. J Immunol 163:5211-5218
19. Tanaka H, Tanaka J, Kjaergaard J et al (2002) Depletion of CD4+CD25+ regulatory T cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 25:207-217 (Pubitemid 34533310)
20. Chen A, Liu S, Park D et al (2007) Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adaptive T cell transfer. Cancer Res 67:1291-1298
21. Mahnke K, Schonfeld K, Fondel S et al (2007) Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120:2723-2733 (Pubitemid 46651297)
22. Van Elsas A, Hurwitz AA, Allison P (1999) Combination of immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-1) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 3:355-366 (Pubitemid 29374833)
23. Maker AV, Attia P, Rosenberg SA (2005) Analysis of the cellular mechanism of anti-tumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746-7754 (Pubitemid 41713475)
24. Gavin MA et al (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nat 445:771-775 (Pubitemid 46279714)
25. Wan YY, Flavel RA (2007) Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445:766-770 (Pubitemid 46279706)
26. Sakaguchi S, Sakaguchi N, Asano M et al (1995) Immunologic self-tolerance maintained by activated T cells express IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151-1164
27. Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in tumor microenvironment. J Immunother 29:233-240
28. Kobie JJ, Wu RS, Kurt RA et al (2003) Transforming growth factor beta inhibits the antigen-presenting functions and anti-tumor activity of dendritic cell vaccines. Cancer Res 63:1860-1864 (Pubitemid 36460849)
29. Chen ML, Pittet MJ, Gorelik L et al (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. PNAS 102:419-424 (Pubitemid 40116782)
30. Park SJ, Nakagawa T, Kitamura H et al (2004) IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol 173:3844-3854 (Pubitemid 39280747)
31. Jonuleit H, Schmitt E, Steinbrink K et al (2001) Dendritic cells as a tool to induce anergic and regulatory T-cells. Trends Immunol 22:394-400 (Pubitemid 32673646)
32. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B et al (2005) Tumor cyclooxygenase-2/prostaglandine E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res 65:5211-5220 (Pubitemid 40827331)
33. Kuroda E, Yamashita U (2003) Mechanisms of enhanced macrophage- mediated prostaglandine E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol 170:757-764 (Pubitemid 36070526)
34. Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD- 1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 7:1027-1034
35. Hwu P, Du MX, Lapointe R et al (2000) Indolamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596-3599 (Pubitemid 30169812)
36. Kim R, Manabu E, Tanabe E et al (2006) Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 66:5527-5536 (Pubitemid 43927099)
37. Sica A, Saccani A, Bottazzi B et al (2000) Autocrine production of IL-10 mediates defective IL-12 production and NFk-B activation in tumor-associated macrophages. J Immunol 164:762-767 (Pubitemid 30043699)
38. Starace D, Riccioli A, D'Alessio A et al (2004) Characterization of signaling pathways leading to Fas expression induced by TNFα: pivotal role of NF-κB. FASEB 19:473-475
39. Shi W, Li L, Shi X et al (2006) Inhibition of nuclear factor-kB activation is essential for membrane-associated TNF-alpha-induced apoptosis in HL-60 cells. Immunol Cell Biol 84:366-373 (Pubitemid 43882842)
40. Baron-Bodo V, Doceur P, Levebre ML et al (2005) Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiolog 210:267-277 (Pubitemid 41025168)
41. Ouyang GF, Saio M, Suwa T et al (2006) Interleukin-2 augmented activation of tumor-associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol 28:1201-1208
42. Miller RA (1996) The aging immune system: primer and prospectus. Science 273:70-74
43. Utsuyama M, Hirokawa K, Kurashima C et al (1992) Differential age-change in the number of CD4+CD45RA+ and CD4+CD29+ T cell subsets in human peripheral blood. Mech Ageing Dev 63:57-68
44. Grubeck-Loebenstein B (1997) Changes in the aging immune system. Biologicals 25:205-208
45. George AJT, Ritter MA (1996) Thymic involution with ageing: obsolescence or good houskeeping? Immunol Today 17:267-272 (Pubitemid 26183490)
46. Tamir A, Eisenbraun MD, Garcia GG et al (2000) Age-dependent alterations in the assembly of signal transduction complexes at the site of T cell/APC interaction. J Immunol 165:1243-1251 (Pubitemid 30604550)
47. Wack A, Cossarizza A, Heltai S et al (1998) Age-related modifications of the human alphabeta T cell repertoire due to different clonal expansions in the CD4+ and CD8+ subsets. Int Immunol 10:1281-1288 (Pubitemid 28414333)
48. EVros RB (2006) Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 7:599-604
49. EVros RB (2004) Replicative senescence of CD8 T cells: effect on human aging. Exp Ger 39:517-524
50. Filaci G, Fravega M, Negrini S et al (2004) Nonantigen-specific CD8+ suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T cell proliferation and CTL function. Hum Immunol 65:142-156 (Pubitemid 38224140)
51. Nishioka T, Shimizu J, Yamazaki S et al (2006) CD4+CD25+ Fox3+ T cells and CD4+CD25-Fox3+ T cells in aged mice. J Immunol 176:6586-6593
52. Gregg R, Smith CM, Clark FJ et al (2005) The number of human peripheral blood CD4+CD25 high regulatory T cells increases with age. Clin Exp Immunol 140:540-546 (Pubitemid 40813966)
53. McElhaney JE, Meneilly GS, Lechelt KE et al (1994) Split-virus influenza vaccines: do they provide adequate immunity in the elderly? Gerontol 49:M37-M43 (Pubitemid 24100243)
54. Quyang Q, Cicek G, Westendorp RGJ et al (2000) Reduced IFNγproduction in elderly people following in vitro stimulation with influenza vaccine and endotoxin. Mech Ageing Dev 121:131-137 (Pubitemid 32115407)
55. Lung TL, Sauerwein-Teissl M, Parson W et al (2000) Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells. Vaccine 18:1606-1612 (Pubitemid 30109516)
56. Sauerwein-Teissl M, Schonitzer D, Grubeck-Loebenstin B (1998) Dendritic cell responsiveness to stimulation with influenza vaccine is unimpaired in old age. Exp Ger 33:625-631 (Pubitemid 128370106)
57. Sprecher E, Becker Y, Kraal G et al (1990) EVect of aging on the epidermal dendritic cell population in C57Bl/6J mice. J Invest Dermatol 94:247-253 (Pubitemid 20059171)
58. Sunderkotter C, Laden H, Luger TA (1997) Aging and the skin immune system. Arch Dermatolog 133:1256-1262 (Pubitemid 27443818)
59. Bella D, Bierti L, Presicce P et al (2007) Peripheral blood dendritic cells and monocytes are differentially regulated in the elderly. Clin Immunol 122:220-228 (Pubitemid 46073895)
60. Agrawal A, Agrawal S, Cao JN et al (2007) Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinisitide 3-kinase-signaling pathway. J Immunol 178:6912-6922 (Pubitemid 46847417)
61. Renshaw M, Rocjwell J, Engleman C et al (2002) Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol 169:4697-4701 (Pubitemid 35217128)
62. Muss HB (2001) Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status. J Natl Cancer Inst Monogram 30:52-55
63. Provinciali M, Argentati K, Tibaldi A (2000) Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther 7:624-632 (Pubitemid 30175567)
64. Provinciali M, Smorlesi A, Donnini A et al (2003) Low effectiveness of DNA vaccination against HER2/neu in aging. Vaccine 21:843-848 (Pubitemid 36126417)
65. Lustgarten J, Dominguez AL, Thomas M (2004) Aged mice develop protective anti-tumor responses with appropriate costimulation. J Immunol 173:4510-4515 (Pubitemid 39280681)
66. Sharma S, Domiguez AL, Lustgarten J (2006) Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB. Exp Ger 41:78-84 (Pubitemid 43031371)
67. Grolleau-Julius A, Abernathy L, Harning E, Yung RL (2008) Mechanisms of murine dendritic cell antitumor dysfunction in aging. Cancer Immunol Immunother. doi: 10.1007/s00262-008-0636-9
68. Gravekamp C, Sypniewska R, Gauntt S, Tarango M, Price P, Reddick R (2004) Behaviour of metastatic and non-metastatic tumors in old mice. Exp Biol Med 229:665-675 (Pubitemid 38878912)
69. Gravekamp C, Leal B, Denny A, Bahar R, Lampkin S, Castro F, Moore D, Reddick R (2008) In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1. Cancer Immunology and Immunotherapy. Cancer Immunol Immunother 57:1067-1077
70. Gravekamp C (2007) Cancer vaccines in old age. Exp Gerontol 42:441-450
71. Gravekamp C, Kim SH, Castro F (2008). Cancer vaccination: manipulation of immune responses at old age. Mech Ageing Dev (in press)
72. Stacy S, Infante AJ, Wall K et al (2003) Recall immune memory: a new tool for generating late onset autoimmune myasthenia gravis. Mech Ageing Dev 124:931-940 (Pubitemid 37130143)
73. Tan JT, Dudl E, LeRoy E et al (2001) IL-7 is critical for homeostatic proliferation and survival of naïve T cells. PNAS 98:8732-8737 (Pubitemid 32678096)
74. Nardin A, Levebre ML, Labroquere K et al (2006) Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 6:123-133
75. Kim SH, Castro F, Gonzalez D, Maciag P, Paterson Y, Gravekamp C (2008) Mage-b delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer 99:741-749
76. Fest S, Heubener N, Weixler S et al (2006) Characterization of GD2 peptide miotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66:10567-10575 (Pubitemid 44799780)
77. DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF (1998) Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 185:65-74 (Pubitemid 28272676)
78. Niethammer AG, Xiang R, Becker JC et al (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369-1375 (Pubitemid 36019421)
79. Fang L, Lonsdorf AS, Hwang ST (2008) Immunotherapy for advanced melanoma. J Invest Dermatol 128:2596-2605
80. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immuno therapy: moving beyond current vaccines. Nature Med 10:999-1015
81. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principle of stem-cell biology to cancer. Nat Rev Cancer 3:895-902 (Pubitemid 37500174)